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Abstract 
Background: Hepatitis E virus infection (HEV) is an emerging problem in developed countries. 
Diagnosis of HEV infection is based on the detection of HEV-specific antibodies, viral RNA and/or 
antigens (Ag). Humanized mice were previously reported as a model for the study of HEV infection, 
but published data was focused on the quantification of viral RNA. However, the kinetics of HEV Ag 
expression during the course of infection remains poorly understood. 
Methods: Plasma and fecal suspensions from HEV infected and ribavirin-treated humanized mice 
were analyzed using HEV antigen ELISA, RT-qPCR, density gradient and Western blotting.  
Result: ORF2 Ag was detected in both plasma and stool of HEV infected mice, and increased 
overtime. Contrary to HEV RNA, ORF2 Ag levels were higher in mouse plasma than in stool. 
Interestingly, ORF2 was detected in plasma of mice that were RNA negative in plasma but RNA 
positive in stool; and after viral clearance by ribavirin. Plasma density gradient analysis revealed the 
presence of the non-infectious glycosylated form of ORF2. 
Conclusion: ORF2 Ag can be used as a marker of active HEV infection and the assessment of antiviral 
therapy, especially when fecal samples are not available or molecular diagnostic tests are not 
accessible. 
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Introduction 
Hepatitis E virus (HEV) causes about 20 million infection annually[1]. HEV is a positive sense single 
stranded RNA virus that belongs to the Hepeviridae family, comprising Orthohepevirus and 
Pescihepevirus genera. The Orthohepevirus A species includes at least 7 genotypes (gt), 5 of which 
were shown to be capable of causing infection in humans[2, 3]. HEV gt1 and gt2 isolates infect 
humans only and are dominant in developing countries, while gt3 and gt4 isolates are zoonotic and 
are more common in industrialized countries[4]. HEV isolates of gt5 and gt6 have been isolated from 
wild boar in Japan and seem not infectious to humans[5]. HEV gt7 was isolated from camels in the 
Middle East[6]. To our knowledge, only one human case was diagnosed with camelid HEV 
infection[7]. More recently, a potential 8thgenotype was identified in Bactrian camels in China[8]. 
There are four major routes of HEV transmission: fecal-oral, food borne, blood transfusion and 
vertical transmission from infected mothers to their babies[1, 4]. Although a typical HEV infection 
will resolve spontaneously, chronicity has been observed in immunocompromised patients[9]. 
Ribavirin (RBV) is the drug of choice for treatment of chronic HEV infection[10, 11]. 
The HEV genome encodes three open reading frames (ORFs); ORF1, ORF2 and ORF3. ORF1 encodes a 
non-structural polyprotein that is essential for viral replication. ORF2 encodes the viral capsid 
protein and is the most immunogenic viral protein. ORF3 encodes a small phosphoprotein that is 
involved in virion morphogenesis and egress[1, 4]. 
The diagnosis of HEV infection is based mainly on the detection of HEV RNA (gold standard) and/or 
detection of anti-HEV antibodies (IgM & IgG)[12]. Recently, a novel diagnostic assay became 
commercially available (Bejing Wantai Biological Pharmaceutical Co., Bejing, China), which is based 
on the detection of HEV ORF2 antigen (Ag). Previous studies showed that this HEV Ag ELISA could be 
used as a diagnostic tool in clinical laboratories where molecular assays are lacking[13-16]. Behrendt 
et al. showed that the sensitivity of the HEV Ag ELISA assay is less than RT-qPCR, especially during 
acute HEV infection, and that higher HEV Ag levels were detected in chronically infected patients 
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compared to acute ones[17]. They also reported that HEV Ag was detectable for more than 100 days 
after HEV RNA clearance in ribavirin treated patient[17]. Moreover, Marion et al., reported that the 
serum level of HEV Ag at the acute phase of HEV infection in immunocompromised patients could 
predict the possibility of HEV chronicity in these patient [18]. Using an HEV cell culture system, 
Montpellier et al., showed that HEV produces 3 different forms of ORF2: infectious/intracellular 
ORF2 (ORF2i), glycosylated ORF2 (ORF2g) and cleaved ORF2 (ORF2c). The ORF2i protein(80KDa) is 
the structural component of infectious viral particles and is not glycosylated. In contrast, ORF2g 
(90KDa) and ORF2c (75KDa) proteins are glycosylated forms that are secreted in large amounts in 
culture supernatant and are not associated with infectious virions. ORF2g and ORF2c do not form 
particulate material but, importantly, are the most abundant antigens in patient sera[19]. Recently, 
Yin et al. reported that the glycosylated secreted form of ORF2 resembles the virus capsid, but lacks 
the antigenic epitope predicated to bind the cell receptor[20]. 
Recently, our group and others have established human-liver chimeric mice as a small animal model 
for the study of HEV infection and the evaluation of novel antiviral therapies [21-26]. Similar to 
immunocompromised patients, these immunodeficient mice (SCID or Rag-2-/--IL-2Rγ-/-) develop 
chronic HEV infection when challenged with different HEV preparations of gt1 and gt3 [21-24]. While 
HEV infection was confirmed in these models by the detection and quantification of HEV RNA in 
mouse stool, plasma, bile and liver tissue, the kinetics and characteristics of HEV antigen expression 
during the course of infection remained unclear. 
In this study, we characterized the ORF2 antigen secretion during the course of HEV infection in 
humanized mice and investigated its potential use as marker for antiviral therapy. 
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Material and Methods 
1-Production, infection and therapy of human liver chimeric mice 
uPA+/+-SCID and FRG mice were transplanted with primary human hepatocytes as previously 
described[21, 23, 27]. Humanized mice were inoculated intrasplenically or orally with fecal 
suspensions or plasma containing HEV of gt1 or gt3. Plasma and fecal samples were regularly 
collected from the inoculated mice. Ribavirin (RBV) treatment was performed at 50 mg/kg as 
previously described [21]. Samples used in this study originated both from mice used in previous 
studies [21, 23, 25] and new infections. Pharmacokinetic analysis of HEV ORF2 antigen in non-
humanized mice are described in the supplemental materials and methods section. All procedures 
were performed according to European and Belgian legislation; and were approved by the Animal 
Ethics Committee of the Faculty of Medicine and Health Sciences of Ghent University. 
2-Detection and quantification of HEV RNA in mouse samples 
Viral RNA was extracted from 10% (w/v) mouse fecal preparations and mouse plasma, HEV RNA was 
detected and quantified as described previously[21].  
3-Detection of HEV Ag in mouse samples 
Detection of HEV Ag in mouse samples was performed using the HEV-Ag ELISAPlus assay (Bejing 
Wantai Biological Pharmaceutical Co., China) according to the manufacturer’s instructions, with 
slight modifications to determine the cut-off (C.O.), as described in the supplementary material and 
methods section.  
4-Density gradient analysis 
Mouse plasma and 10% (w/v) mouse stool suspensions were prepared from HEV-infected and non-
infected mice, and were ultra-centrifuged as previously described[21]. More details are available in 
the supplementary material and methods section 
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5- Statistic analyses 
The geometric mean of the viral load and HEV Ag level was determined in mouse samples at the 
start of RBV therapy and EOT. Statistical significance was calculated by GraphPad Prism version 6.1 
using a paired two-tailed Student’s t-test.  
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Results 
1- Kinetic analysis of HEV Ag secretion in HEV-infected human-liver chimeric mice 
Plasma and 10% (w/v) fecal suspensions from HEV infected humanized mice were analyzed for HEV 
RNA and ORF2 Ag. The HEV RNA data was extensively described in our previous publications[21, 23], 
but we here correlate the viral RNA levels with the amount of ORF2 antigen present in each sample. 
In parallel to the HEV RNA load, the level of HEV Ag increased over time in both plasma and 10% w/v 
fecal preparations of HEV gt1 (Figure 1) and gt3 (Figure 2) infected mice. Similar to the HEV RNA 
load, the observed HEV Ag levels were considerably higher in HEV gt1-infected mice compared to 
those in gt3-infected mice (Figure 1 and 2). 
When comparing the ratio of HEV RNA to HEV ORF2 Ag, we observed an overall inverse relation 
between the plasma and the feces. Plasma contained relatively higher levels of ORF2 Ag than HEV 
RNA, while at the corresponding time points the relative level of viral RNA in fecal suspensions was 
higher than the amount of ORF2 Ag (Figure 1). This indicates that the large amounts of ORF2 Ag 
present in mouse plasma likely correspond to non-infectious ORF2 Ag, as previously shown for 
human sera [19]. 
HEV ORF2 Ag levels were very low (near or below cut-off) in mouse stool samples, especially during 
the early phase of infection where the viral load was already relatively high in most animals (RNA 
level up to 105-106 IU/ml)(Figure 1 and 2). In one mouse, the viral RNA was detectable in stool by RT-
qPCR (Figure 2B) starting from week 2 until week 16 post inoculation. However, HEV ORF2 levels 
remained below cut-off in all tested fecal samples. On the other hand, HEV ORF2 Ag was detected in 
certain mouse plasma samples in which HEV RNA was under limit of detection (Figure 2A and C), 
confirming our hypothesis that the non-infectious forms of ORF2 were abundantly present in mouse 
plasma. 
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As can be seen in Figure 1 and 2, ORF2 levels increased over time, especially in HEV gt1-infected 
mice, but this increase was not always concomitant with an increase in HEV RNA load. In one mouse 
(Figure 1C), viremia was nearly stable during the course of infection, but the ORF2 Ag level increased 
sharply over the same 5-week period. This again suggests that the non-infectious forms of ORF2 
accumulate in the plasma of infected mice. 
2- ORF2 status in humanized mice with low HEV replication and in mice after oral HEV challenge. 
Next, we examined the HEV ORF2 Ag status in samples obtained from mice with low HEV replication. 
In these mice, the viral load was under limit of quantification (LOQ) in the plasma during the course 
of HEV infection, while HEV RNA was continuously detectable in feces but at a relatively low level 
(2x103 to 5x104 IU/ml). As shown in Figure 3, HEV ORF2 was not detected in any of the tested plasma 
and stool samples. 
Similarly, we evaluated whether HEV ORF2 could be detected in humanized mice that were orally 
inoculated with multiple HEV preparations. We have previously shown that oral inoculation does not 
lead to HEV infection and that HEV RNA remains under LOD in the plasma and stool[21, 23]. Here, 
we detected ORF2 only the first week after inoculation, and only in stool suspensions (Supplemental 
Figure 1). HEV ORF2 was never detected in any of the subsequent samples. 
3- Characterization of HEV ORF2 present in mouse samples 
Iodixanol density gradient centrifugation was performed on mouse plasma and 10% (w/v) mouse 
stool suspensions collected at different time points after viral inoculation to evaluate which of the 
different ORF2 forms were present. RT-qPCR, HEV ORF2 Ag ELISA and WB analysis were performed 
on each fraction. We first focused on the analysis of mouse plasma samples collected before and 1, 5 
and 10 weeks after infection. As shown in Figure 4, the peak of HEV RNA was identified in fraction 6 
(density 1.11 g/l), while the peak of HEV Ag was always observed in fraction 4(density 1.09 g/l). One 
week after viral inoculation, HEV ORF2 was detected by ELISA in fraction 4 and not in the RNA 
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enriched infectious fraction 6. Western blot analysis confirmed the observations made by ELISA and 
revealed that the ORF2g protein (90 kDa non-infectious glycosylated form) was the only form 
detectable in plasma.  
At later time points (week 5 and 10 post-infection), HEV ORF2 Ag became detectable in more density 
gradient fractions, confirming our previous observation that the secretion of HEV ORF2 Ag is a slow 
and accumulative process. HEV ORF2 was detected in different mouse plasma fractions which did 
not contain HEV RNA. Western blot analysis revealed that the ORF2g protein remained the major 
ORF2 form in mouse plasma at these later time points (Figure 4). We did not detect the infectious 
ORF2form (ORF2i) in any of the mouse plasma fractions at any time point. 
Density gradient analysis of fecal samples revealed that the peak of HEV RNA and HEV ORF2 Ag was 
found in fraction 10 (1.16 g/l) and fraction 3(1.07 g/l), respectively (Supplementary Figure 2A). The 
relative amount of HEV ORF2 Ag was lower in stool fractions compared to plasma fractions, while 
this was the opposite for the HEV RNA level. Again, HEV ORF2 Ag was not detected by ELISA in the 
stool infectious fraction (fraction 10). In addition, we did not visualize any form of ORF2 in the stool 
fractions using Western blotting (data not shown). Unlike the HEV RNA distribution, the distribution 
of HEV ORF2 Ag among the different stool fractions was similar to the distribution of ORF2 Ag among 
plasma fractions (Supplementary Figure 2B and C). 
4-Kinetics of HEV ORF2 Ag in humanized mice during the course of ribavirin therapy 
Five HEV infected humanized mice underwent a 2-week ribavirin (RBV) therapy at 50 mg/kg. HEV 
ORF2 Ag and HEV RNA were tested both in plasma and 10% (w/v) stool suspensions at 3 different 
moments: start of therapy (SOT), end of therapy (EOT) and at viral relapse. Similar to the effect on 
viral RNA load, RBV therapy caused a reduction in the level of ORF2 in both the stool and the plasma 
of the treated mice (Figure 5). Although, the reduction in viremia was more pronounced than the 
reduction in fecal RNA load, the reduction of ORF2 in plasma was less than the reduction in fecal 
ORF2Ag. At the SOT, the geometric mean of fecal RNA load and HEV Ag level in five mice was 5.1x106 
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IU/ml and 12.48 A/C.O., respectively, and were reduced at EOT to 2.05x105 IU/ml and 3.75 A/C.O., 
respectively (Figure 5A and B). While the geometric mean of viremia and plasma HEV Ag level in 
these mice at the start of therapy were 2.95x104 IU/ml and 26.1 A/C.O., respectively, and their levels 
were reduced to the limit of quantification (LOQ=4.05x102 IU/ml) and 14.49 A/C.O., respectively at 
EOT (Figure 5A and B).The reduction in the fecal HEV Ag, but not plasma HEV Ag, was statistically 
significant (P=0.0008)(Figure 5A). Interestingly, the level of HEV Ag was increased again in both the 
plasma and stool of the treated mice after cessation of therapy (Figure 5C). 
5- Assessment of in vivo stability of HEV ORF2 
In order to evaluate how long ORF2 remains detectable in plasma and feces after secretion from the 
liver, we inoculated two groups of non-humanized mice with iodixanol cushion-isolated HEV ORF2 
preparations containing either the three forms of ORF2 (ORF2i, ORF2g and ORF2c), or the non-
infectious form of ORF2 (ORF2g and ORF2c). The amount of HEV RNA and ORF2 protein present in 
plasma and feces were quantified daily. HEV ORF2 Ag was detectable in mouse stool and plasma of 
both groups, but the level decreased gradually until ORF2 disappeared completely within 1 week 
(Supplementary Fig 3). HEV RNA was under LOQ in all tested samples. 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article-abstract/doi/10.1093/infdis/jiz171/5475180 by G
hent U
niversity user on 30 April 2019
Ac
ce
pte
d M
an
us
cri
pt
 
11 
 
Discussion 
HEV virus infection is mainly diagnosed by detection of HEV-specific IgM antibodies and/or detection 
of HEV RNA. A diagnostic ELISA assay based on the detection of HEV ORF2 Ag in patient plasma 
samples became recently commercially available. The sensitivity and specificity of this assay was 
reported previously[13-15, 17], and it is recommended in clinical settings where molecular diagnosis 
is not available. HEV Ag can be used as a diagnostic marker in the window period and in chronic HEV 
infection, especially in immunocompromised patients in whom seroconversion may be delayed or 
absent[15, 17, 28, 29].The kinetics of HEV Ag detection during the course of HEV infection is not 
known. Here, we used human liver chimeric mice (uPA-SCID and FRG background) to study the 
kinetics of HEV Ag expression during the course of HEV infection and therapy. Since the adaptive 
immune system is lacking in these mice, chronic HEV infection is developed when these mice are 
challenged with HEV preparations.  
HEV Ag was detected in both mouse plasma and stool preparations of HEV infected humanized mice. 
In addition, the Ag level increased with time suggesting that HEV Ag is a relevant marker of active 
HEV replication. The level of HEV Ag was higher in mouse samples at later time points of infection, 
indicating that the production of HEV Ag is cumulative. In a similar manner, Behrendt et al.reported 
that the HEV Ag level can differentiate between acute and chronic HEV infection; i.e. higher HEV Ag 
levels were detected in chronic HEV infected patients [17]. HEV Ag levels were higher in HEV gt1 
infected mice than in HEV gt3 infected mice, confirming our previous data showing that HEV gt3 is 
less virulent than HEVgt1[21]. In contrast to the HEV RNA load, HEV Ag was relatively higher in 
mouse plasma than in fecal suspensions. In addition, HEV Ag was detected in a few plasma samples 
that scored negative for HEV RNA, suggesting that detected Ag likely corresponds to non-infectious 
ORF2 proteins. Our results are in agreement with previous studies that proposed that non-infectious 
ORF2 proteins are the major antigens in cell culture supernatant and patient sera[19]. Previous 
studies showed that the ratio of HEV Ag/RNA was significantly higher in the urine compared to the 
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serum of the same patient [18, 30]. In humanized mice, the liver is the main site of infection and 
previously we could not detect HEV RNA in the kidney nor the brain of the infected mice [25].  
HEV Ag was not be detected in HEV infected mice which were non-viremic and in which the fecal 
viral load was relatively low. This is probably due the limited amount of Ag secreted into the plasma 
that was too low to be detectable by ELISA. Our results suggest that in case low-level HEV replication 
is expected, qPCR analysis on stool samples is the best option for diagnosis, especially in 
immunocompromised patients where seroconversion is delayed. Similarly, several groups reported 
that HEV-Ag ELISA assay is less sensitive than PCR especially when the viral load is low [12, 14, 15, 
17]. In addition, HEV Ag was not detected in mice that were inoculated orally  with HEV 
preparations, thereby confirming our previous observation that the oral route is not a suitable way 
to establish HEV infection in humanized mice [21, 23], probably due to lack and/or different essential 
receptors in the murine (non-humanized) gut.  
Analysis of mouse gradient fractions showed that the peak of HEV Ag is different from the peak of 
HEV RNA. The peak of HEV RNA in mouse stool sample was 1.16 g/l and the peak of HEV RNA in 
mouse plasma was 1.11 g/l. This difference may be attributed to the presence of lipids around or 
associated with the virions that circulate in the plasma [21]. On the other hand, the distribution of 
HEV Ag in plasma was similar to that in stool. The ORF2g protein was the major ORF2 form detected 
in mouse plasma. Our results agree with Montpellier et al., who showed that the peak of HEV Ag in 
patient plasma samples was at 1.08 g/l, and non-infectious ORF2 proteins (ORF2c/ORF2g) were the 
major Ag present[19]. HEV Ag could be detected in some mouse plasma fractions that were devoid 
of viral nucleic acid. Similarly, Behrendt et al. detected HEV Ag in all gradient fractions of HEV patient 
sera suggesting the presence of distinct fragments of the viral capsid protein with different 
densities[17]. The presence of high levels of non-infectious ORF2 in mouse plasma might also explain 
the low infectivity of plasma preparation compared to stool preparation [21, 23].The amount of HEV 
Ag present in mouse stool fraction was relatively low, which impeded its characterization by WB.  
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Next, we tested the effect of RBV therapy on the HEV Ag level in mouse samples. We found that RBV 
causes a reduction in both the plasma and fecal HEV Ag level, and the reduction was statistically 
significant in mouse stool samples but not in plasma. In all treated mice, the reduction of HEV Ag 
was concomitant with the reduction of HEV RNA in mouse stool, while most mice became non-
viremic at EOT, HEV Ag remained detectable in mouse plasma. This indicates that viral Ag remains 
present in mouse plasma even after clearance of infection. Our results agree with Behrendt et al., 
who reported that HEV Ag could be detected in patient plasma for more than 100 days after HEV 
clearance. Similarly, prolonged fecal shedding has been shown in patients on RBV therapy, despite 
undetectable viremia [21, 31, 32]. 
The apparent effect of RBV therapy on HEV infection depends on the viral marker of interest and the 
compartment analyzed. Our data indicates that in plasma RBV especially has an effect on the 
secretion of infectious viral particles (HEV RNA) and less on secreted ORF2 that is not associated with 
RNA. The differential effect on plasma versus fecal RNA suggests that when RBV interferes with viral 
replication, the available viral RNA is preferentially packaged into particles that are secreted into the 
bile-canalicular pathway rather than those secreted into plasma. Our results are in agreement with 
recent data published by Capelli et al., who reported that infectious HEV particles are mainly 
released to the bile , while only small fractions are released to the blood[33]. Importantly, HEV Ag 
levels increased after therapy cessation indicating that HEV Ag can be also used as a surrogate 
marker for HEV relapse. 
Finally, we assessed the in vivo stability of HEV ORF2 in absence of HEV replication, i.e. after 
injection in non-humanized mice. HEV ORF2 gradually disappeared within 1 week from both feces 
and plasma, while viral RNA immediately became undetectable. This is faster than what we observed 
in our RBV treatment study, indicating that during treatment there was remaining low-level viral 
replication and protein secretion into the plasma. Hence also explaining the presence of HEV RNA 
and Ag in the mouse stool and relapse after therapy cessation. Although the study by Behrendt et al. 
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did not mention any stool data, the persistence of HEV Ag in the patient plasma after RBV therapy 
must have been due to same reason. Further studies are needed to ascertain this point. 
In conclusion, our results show the kinetics of HEV Ag during the course of HEV infection, therapy 
and relapse. The differential impact of RBV therapy on viral RNA and antigen depending on the 
samples type (feces vs. plasma) is important for the interpretation of HEV diagnosis and evaluation 
of anti-HEV therapy, especially for laboratories where molecular diagnosis is not available and HEV 
Ag is the only diagnostic marker available. 
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Figure 1: Evolution of HEV ORF2and viral RNA in genotype 1 (gt1)HEV-infected humanized mice. 
Humanized mice (n=4) were inoculated with HEV of gt1 ( SAR-55 strain). HEV RNA (solid line; IU/ml, 
left Y-axis) and HEV ORF2 (dotted line; A450/630/C.O., right axis) were measured at different time 
points after inoculation in both mouse plasma (red) and feces (black). LOQ: limit of quantification. 
C.O.: cut-off. Each panel (A, B, C and D) represents data from individual mice. 
 
Figure 2: Evolution of HEV ORF2 and viral RNA in genotype 3 (gt3)HEV-infected humanized mice. 
Humanized mice (n=4) were inoculated with an HEV patient isolate of gt3. HEV RNA (solid line; 
IU/ml, left Y-axis) and HEV ORF2 (dotted line; A450/630/C.O., right axis) were measured at different 
time points after inoculation in both mouse plasma (red) and feces (black). LOQ: limit of 
quantification. C.O.: cut-off. Each panel (A, B, C and D) represents data from individual mice. 
 
Figure 3: Absence of HEV ORF2 Ag in humanized mice with low HEV replication. Humanized mice 
were inoculated with HEV of gt3 (panel A, n=3) or HEV of gt1 (panel B, n=2). Viral RNA (solid line; 
IU/ml, left Y-axis) and ORF2 protein (dotted line; A450/630/C.O., right axis) were measured at different 
time points after inoculation. Black lines represent data obtained from mouse stool, while red lines 
represent data obtained from mouse plasma analyses. LOQ: limit of quantification. C.O.: cut-off. 
 
Figure 4: Mouse plasma density gradient analysis during the course of HEV infection. 
Plasma collected before HEV infection (week 0) and at different time points post infection (week 1, 5 
and 10)was processed by iodixanol density gradient ultracentrifugation and the gradient fractions 
were analyzed by Western blotting,ORF2-specific ELISA and RT-qPCR. HEV RNA levels (left Y-axis) are 
represented by black lines, while HEV ORF2 Ag levels are shown in green. 
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Figure 5: Kinetics of HEV Ag during ribavirin therapy in humanized mice. 
Humanized mice (n=5) were treated orally with RBV for 2 weeks. HEV Ag (A) and HEV RNA (B) were 
measured at start (SOT) and end of therapy (EOT). HEV Ag was monitored in two humanized after 
RBV therapy cessation (C). Fecal and plasma data are shown in black and red respectively. Horizontal 
lines represent the geometric mean. LOQ: is limit of quantification. 
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Figure 4 
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Figure 5 
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